Can You Get BPC-157 Prescribed in the United States?

As of late October 2026, a U.S. physician may write a patient-specific compounded prescription for BPC-157 under the FDA’s interim enforcement-discretion policy, even though the peptide still lacks an FDA-approved product and is not on the 503A “clinical-need” bulk list. A limited number of clinicians now order BPC-157 from 503A pharmacies that follow the policy; quality and legal risks remain if a supplier fails to meet the required standards. Because the peptide is still unapproved, many pharmacies choose not to dispense it, and patients should avoid unregulated “research-use only” sources.

• BPC-157 is not FDA-approved for any indication and has no official dosing guidelines. (fda.gov)
• The FDA classifies BPC-157 as a Category 2 bulk drug substance, meaning it should not be compounded for human use. (fda.gov)
• Doctors may prescribe other anti-inflammatory drugs, such as prednisone, that have proven safety data instead of unapproved peptides.
• In July 2026, an FDA advisory committee reviewed BPC-157 for potential inclusion on the 503A Bulks List but has not yet issued a final decision. (fda.gov)
• Products sold online as “research only” BPC-157 are often contaminated or mislabeled, according to independent peptide testing. (thepeptidefoundation.org)

What BPC-157 Is: a research peptide, not an approved drug

BPC-157 is a 15-amino-acid fragment derived from a naturally occurring gastric protein called body protection compound. Pre-clinical studies suggest it may promote angiogenesis and tissue repair, which explains the interest in injury recovery. However, there are no completed Phase II or III human trials. Without that evidence the molecule remains classified as a research peptide, not a medication.

You can dive deeper into the science in our companion article How BPC-157 Works.

Why BPC-157 Lacks FDA Approval

The FDA evaluates new drugs through Investigational New Drug (IND) and New Drug Application (NDA) processes. No sponsor has submitted an NDA for BPC-157. In 2024 the agency placed the peptide in Category 2 of its interim 503A bulks policy, a holding zone for substances that raise safety concerns or lack sufficient data. (fda.gov)

Advisory committee spotlight: On July 23 2026 the Pharmacy Compounding Advisory Committee (PCAC) discussed moving BPC-157 onto the 503A Bulks List. The panel’s preliminary vote was 6 to 5 against recommending inclusion, citing data gaps in toxicity and human efficacy. The FDA has not announced a final ruling as of October 2026. (fda.gov)

Can Doctors Legally Prescribe BPC-157?

U.S. doctors have broad authority to prescribe FDA-approved drugs off-label. Because BPC-157 is not approved, it must be written as a compounded prescription. Under the new interim enforcement-discretion policy, a physician can direct a compliant 503A pharmacy to prepare the peptide for an individual patient, even though no FDA-approved source product exists. Providers who use pharmacies that do not follow the policy still face regulatory risk.

Most clinicians instead use approved anti-inflammatory or pain medications such as naproxen or ibuprofen while patients await more data.

How Compounding Rules Limit Access

503A pharmacies normally may prepare customized medications only when the ingredient appears on the FDA’s approved Bulks List or is part of an approved drug. The October 28 2026 interim policy carves out an exception: 503A pharmacies may compound BPC-157 for an individually named patient if they meet specific quality, labeling, and adverse-event-reporting conditions. (peptiderank.org)

503B outsourcing facilities face even stricter bulk-ingredient limits, so BPC-157 is also off-limits there. Importing finished vials from overseas skirts the law and invites FDA seizure.

Paths Patients Are Using Today

Despite the legal hurdles, three main routes exist in the wild:

1. Telehealth clinics working with compounders. Some online peptide startups advertise “prescription BPC-157.” They usually ship from a small out-of-state 503A pharmacy; you’ll want to confirm the pharmacy is following the new FDA interim guidance, because non-compliant operations can still be shut down without warning, leaving patients mid-course.

2. Research chemical websites. These sites sell BPC-157 labeled “NOT FOR HUMAN USE.” Independent tests have found vials with as little as 60 % of the stated peptide and bacterial contamination. (thepeptidefoundation.org)

3. International travel or mail-import. Bringing peptide vials across the border violates customs rules. The FDA can detain or destroy shipments.

You can read more about risky supply chains in Peptide Regulations: What Buyers Should Know.

How to Verify a Legitimate Peptide Prescription

Until the FDA issues a final ruling, use this checklist before paying any clinic:

Prescriber transparency: The ordering clinician’s full name, state license, and contact should appear on every document.

Pharmacy license lookup: Verify the compounding pharmacy on your state board’s public site.

Ingredient disclosure: A true 503A label lists the peptide lot number, expiry (typically 28–60 days), and USP <797> sterile-testing results.

For more tips, see Guide to Peptide Prescriptions.

Risks and Safety Concerns to Consider

Unknown toxicity: Rodent studies report increased vascular growth, which raises theoretical cancer risk. Long-term human data are absent.

Contamination: A 2025 survey of 30 retail peptide vials found endotoxin levels above USP limits in 27 % of samples. (thepeptidefoundation.org)

Drug-testing implications: BPC-157 is on the World Anti-Doping Agency’s Prohibited List. Athletes who test positive may face suspensions.

Side-effect profiles are covered in our detailed BPC-157 Side-Effects & Safety Guide.